2 years of history · ending 2025-12-31 · SEC EDGAR
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 19.00% | 19.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | — | — | — | — | — | 7.55% |
| Foreign Rate Differential | — | — | — | — | — | — |
| Other Adjustments | — | — | — | — | — | — |
| R&D Tax Credits | — | — | — | — | — | 1.57% |
| Effective Tax Rate | -19.13% | 28.39% | 21.26% | 6.32% | -92.96% | 27.41% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | −$145.0M | −$186.0M | −$61.0M | −$9.0M | $66.0M | $40.0M |
| Income Taxes Paid (Cash) | −$13.0M | −$5.0M | −$1.0M | $2.0M | $14.0M | $52.0M |
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Total Consideration
$597.0M
Share price: $7.50
Purchase-Price Allocation
Goodwill
$348.0M
Intangibles
$351.0M
Assets Acquired
$1.19B
Liabilities Assumed
$594.0M
Deferred Tax Liability
$75.0M
Pro-Forma Combined Entity
Revenue
$3.15B
Net Income
+$72.0M
Purchase-Price Allocation
Goodwill
$81.0M
Per-category restructuring disclosures sourced from us-gaap:RestructuringCostAndReserveAxis dimensional XBRL. Negative charges indicate reversals of prior accruals (a sign the original estimate was too aggressive — flattering current-period earnings).
As of 2025-12-31
| Category | Class | P&L Charge | Cash Paid | Reserve Balance |
|---|---|---|---|---|
| Other Restructuring | Other | +$48M | — | — |
| Facility Lease Related | Facility Closing | — | — | — |
| Facility Non Lease Related | Facility Closing | — | — | $5M |
| Employee Severance | Employee Severance | — | — | $30M |
Phase 1: currency selection stored in the URL. Conversion ships in Phase 2 (see ADR-0003).
